Medicherla et al. found that the blocking of TGF-β signaling with galunisertib or LY2109761 reduces tumor stromal content and inhibits the synthesis of connective tissue growth factor by downregulating fibroblastic-cell proliferation in hepatocellular carcinomas [110]. Here, TGFB1 is linked to neoplasm.